We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
Read MoreHide Full Article
Key Takeaways
AbbVie's oncology revenues fell 3% in Q1 as Imbruvica sales dropped nearly 25% year over year.
ABBV's Venclexta sales rose nearly 10% on strong demand in CLL combination regimens.
Epkinly revenues jumped 58% while Elahere sales increased more than 8% in the quarter.
AbbVie’s (ABBV - Free Report) oncology portfolio delivered a slight decline in the first quarter of 2026, as the segment was affected by weak sales of the blood cancer drug Imbruvica. The company generated oncology revenues of $1.63 billion in the quarter, down 3% year over year on an operational basis.
The biggest growth contributor within the segment remained Venclexta, which recorded sales of $770 million, up nearly 10% year over year. The uptick was attributed to strong demand in chronic lymphocytic leukemia (CLL), driven by the combination use with BTK inhibitors. During the earnings call, management highlighted continued momentum for the drug, noting that BTK-based combination regimens are increasingly becoming a preferred treatment approach globally.
AbbVie’s newer oncology products continued to show encouraging growth trends. Sales of ovarian cancer therapy Elahere rose more than 8% year over year to $198 million in the quarter, while lymphoma drug Epkinly recorded revenues of $83 million, up about 58%.
However, these gains were offset by a sharp decline in Imbruvica sales, which fell nearly 25% year over year to $556 million. AbbVie attributed the decline to competitive pressure, as well as the impact of Medicare drug pricing changes under the Inflation Reduction Act. Management stated that newer oncology medicines partially offset the expected decline in Imbruvica sales.
For AstraZeneca, oncology sales now account for 44% of total revenues. Sales in its oncology segment rose 16% year over year in first-quarter 2026, driven by strong performance of medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 49% of MRK’s total revenues in first-quarter 2026.
Pfizer’s oncology revenues grew 7% in first-quarter 2026, driven by drugs like Padcev, Lorbrena, the Braftovi-Mektovi combination and Tukysa. The segment now accounts for more than 26% of its total revenues.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price-to-earnings (P/E) ratio, the company’s shares currently trade at 14.11 times forward earnings, below the industry average of 17.42.
Image Source: Zacks Investment Research
ABBV’s EPS estimates for 2026 and 2027 have increased during the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
Key Takeaways
AbbVie’s (ABBV - Free Report) oncology portfolio delivered a slight decline in the first quarter of 2026, as the segment was affected by weak sales of the blood cancer drug Imbruvica. The company generated oncology revenues of $1.63 billion in the quarter, down 3% year over year on an operational basis.
The biggest growth contributor within the segment remained Venclexta, which recorded sales of $770 million, up nearly 10% year over year. The uptick was attributed to strong demand in chronic lymphocytic leukemia (CLL), driven by the combination use with BTK inhibitors. During the earnings call, management highlighted continued momentum for the drug, noting that BTK-based combination regimens are increasingly becoming a preferred treatment approach globally.
AbbVie’s newer oncology products continued to show encouraging growth trends. Sales of ovarian cancer therapy Elahere rose more than 8% year over year to $198 million in the quarter, while lymphoma drug Epkinly recorded revenues of $83 million, up about 58%.
However, these gains were offset by a sharp decline in Imbruvica sales, which fell nearly 25% year over year to $556 million. AbbVie attributed the decline to competitive pressure, as well as the impact of Medicare drug pricing changes under the Inflation Reduction Act. Management stated that newer oncology medicines partially offset the expected decline in Imbruvica sales.
ABBV’s Competition in the Oncology Space
Other bigger players in the oncology space include AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
For AstraZeneca, oncology sales now account for 44% of total revenues. Sales in its oncology segment rose 16% year over year in first-quarter 2026, driven by strong performance of medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 49% of MRK’s total revenues in first-quarter 2026.
Pfizer’s oncology revenues grew 7% in first-quarter 2026, driven by drugs like Padcev, Lorbrena, the Braftovi-Mektovi combination and Tukysa. The segment now accounts for more than 26% of its total revenues.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price-to-earnings (P/E) ratio, the company’s shares currently trade at 14.11 times forward earnings, below the industry average of 17.42.
Image Source: Zacks Investment Research
ABBV’s EPS estimates for 2026 and 2027 have increased during the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.